ENTROPY NEURODYNAMICS LIMITED — Board/Management Information 2024

Nov 5, 2024

ASX Release

6 November 2024

==> picture [210 x 48] intentionally omitted <==

Resignation of Non-Executive Director

---

Melbourne, Australia – Tryptamine Therapeutics Limited (‘ Tryp ’, ‘ TYP ’ or the ‘ Company ’) ( ASX: TYP ), a clinical-stage biotechnology company wishes to advise that Non-Executive Director Mr Peter Molloy will resign from the Board of Directors.

Mr Molloy’s resignation follows the Company’s strategic placement to raise $6m to fast track its TRP-8803 (IV-infused psilocin) clinical trial strategy, which has also led to the pending appointment of Dr Daniel Tillett as a Non-Executive Director (refer ASX announcement: 30 October 2024).

Mr Molloy has been a member of the Company since September 2020 and was influential in Tryp’s growth trajectory. He provided valued support in the Company’s transition to the Australian Securities Exchange (‘ASX”) (refer ASX announcement: 29 May 2024). The Company wishes to thank Mr Molloy for his service and wish him well for future endeavours.

Dr Tillett’s appointment and Mr Molloy’s resignation will occur after the conclusion of the Company Annual General Meeting, scheduled for Friday 8 November 2024.

Non-Executive Chairman, Mr Mark Davies said: “On behalf of the Board, I would like to thank Peter for his ongoing contribution to the Company in recent years and wish him well for future endeavours. His resignation follows the achievement of a key milestone in the Company’s clinical development pathway, which was followed by a strategic placement and the appointment of Dr Daniel Tillett. Dr Tillett’s appointment forms part of Tryp’s strategy to add clinical expertise to its Board and management team, as the Company moves to the next phase of its flagship clinical development program in the Australian market.”

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome.

==> picture [210 x 47] intentionally omitted <==

Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.tryptherapeutcs.com.

Investor & Media Contact

Jason Carroll Chief Executive Officer Tryptamine Therapeutics Limited jcarroll@tryptherapeutcs.com

Henry Jordan Six Degrees Investor Relations +61 (0) 431 271 538 henry.jordan@sdir.com.au

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp’s Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.